A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.
Beatriz ArnsJaqueline Driemeyer Correia HorvathGabriela Soares RechGuilhermo Prates SesinCrepin Aziz Jose Oluwafoumi AganiBruna Silveira da RosaTiago Marcon Dos SantosLiliane Spencer Bittencourt BrochierAlexandre Biasi CavalcantiBruno Martins TomaziniAdriano Pereira PagliaViviane Cordeiro VeigaGiovana Marssola NascimentoAndre C KalilAlexandre Prehn ZavasckiPublished in: Infectious diseases and therapy (2023)
ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE).
Keyphrases
- gram negative
- multidrug resistant
- clinical trial
- open label
- drug resistant
- phase ii
- phase iii
- acinetobacter baumannii
- study protocol
- klebsiella pneumoniae
- randomized controlled trial
- staphylococcus aureus
- early onset
- phase ii study
- double blind
- escherichia coli
- pseudomonas aeruginosa
- cystic fibrosis
- placebo controlled
- radiation therapy